Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

• 作者: Meiting Chen Zhao Wang Xiaojie Fang Yuyi Yao Quanguang Ren Zegeng Chen Ying Tian Fei Pan Xiaoqian Li Zhiming Li Qingqing Cai He Huang Tongyu Lin
• 来源期刊: 癌症生物学与医学（英文版）
• 年，卷（期）: 2021,（3）
• 所属期刊栏目: ORIGINAL ARTICLE
• 页码范围: 833-840
• 页数: 8页
• 语种: 英文
• DOI: 10.20892/j.issn.2095-3941.2020.0314

摘要

Objective: To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma. Methods: We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to September 2019 at Sun Yat-sen University Cancer Center. We studied a dose-modified and long-course R-CODOX-M/IVAC regimen utilizing a low dose of 1.0 g/m2/cycle cyclophosphamide, 2 g/m2/cycle methotrexate, 4,500 mg/m2/cycle ifosfamide, and 4.0 g/m2/cycle cytarabine. Forty-nine patients with low risk disease underwent 4–6 cycles of dose-modified R-CODOX-M-based chemotherapy. Seventy-four patients with high risk disease underwent 6–8 cycles of dose-modified alternating R-CODOX-M/IVAC regimens. Results: The objective remission was 87.0％. The event-free survival rate and overall survival at 3 years were 81.2％ and 92.1％, respectively. Major grade 3–4 adverse events included leukopenia (91.9％), anemia (58.5％), thrombocytopenia (73.2％), and febrile neutropenia (48.8％). A total of 26.0％ and 37.4％ of patients received red blood cell and platelet transfusions, respectively. We observed 4 cases (3.3％) of septic shock after chemotherapy. Two treatment-related deaths occurred from severe infection. Conclusions: The modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population, with a lower toxicity than standard regimens.